|Brand Name:||Alprax XR|
|Therapeutic Class:||Benzodiazepine sedatives|
|Manufacturer:||Opsonin Pharma Ltd.|
|Last Updated:||2020-11-22 18:15:00|
Alprax XR Tablet contains Alprazolam. Alprax XR uses:
Alprax XR Tablet contains Alprazolam 2 mg. Alprax XR doses:
Treatment should be initiated with a dose of 0.25 to 0.5 mg three times daily. Depending on the response, dose may
be increased at intervals of 3 to 4 days in increments of no more than 1 mg per day. The maximum dose should not
exceed 4 mg/day. Occasional patients with panic disorder may need as much as 10 mg a day to achieve a
successful response and in these cases periodic reassessment and consideration of dosage adjustment is required.
Dosage should be individualized for maximum beneficial effect with a lowest possible dose. If side-effects occur at
starting dose, dose may be lowered. When discontinuing therapy, dosage should be reduced gradually by no more
than 0.5 mg every three days.
In elderly patients or in patients with advanced liver disease, the usual starting dose is 0.25 mg, two or three times
daily and may be gradually increased if needed and tolerated. Safety and effectiveness of Alprax XR Tablet in individuals
below 18 years of age have not been established.
Alprax XR Tablet XR 1 should be administered once daily, preferably in the morning by patients who are on multiple dosage
regimen of Alprax XR Tablet 0.25/0.5 mg. The tablets should be taken intact, they should not be chewed, crushed, or broken.
Side effects, if occur, are generally observed at the beginning of therapy and usually disappear upon continued medication. The most frequent side effects are drowsiness and light headedness. The other side effects, that may occur include depression, headache, confusion, dry mouth, constipation etc.
Alprax XR Tablet is a triazolo analogue of the 1,4-benzodiazepine class of drugs. It is an anxiolytic with hypnotic and anticonvulsive properties. Alprax XR Tablet is presumed to produce its effects via interacting with the Gamma Aminobutyric Acid (GABA) - benzodiazepine receptor complex. Like all benzodiazepines, it causes a dose related CNS depressant activity varying from mild impairment of task performance to hypnosis.
Because Alprax XR Tablet may produce psychological and physical dependence, increment of dose or abrupt discontinuation of Alprax XR Tablet therapy should not be done without physician's advice. Duration of therapy must be determined by the physicians. Alprax XR Tablet should be administered with caution to patients with hepatic or renal disease, chronic pulmonary insufficiency or sleep apnea.
Alprax XR Tablet produces additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol and other drugs which themselves produce CNS depression.
Pregnancy: Alprax XR Tablet has been categorized in pregnancy category D; that means, it should be avoided in pregnancy.
Lactation: Like other benzodiazepines, Alprax XR Tablet is assumed to be excreted in breast milk. Therefore, nursing should not be undertaken by mothers who must use Alprax XR Tablet.
Contraindicated in patients with hypersensitivity to alprazolam or other benzodiazepines. Alprax XR Tablet is also contraindicated in patients with myasthenia gravis, acute narrow angle glaucoma, during pregnancy and also in infants.
Use in Children: Safety and efficacy of Alprax XR Tablet in patients under the age of 18 years has not been established.
Manifestations of Alprax XR Tablet over dosage include somnolence, confusion, impaired coordination, diminished reflexes and coma. In such cases of over dosage general supportive measures should be employed along with immediate gastric lavage.
The CNS-depressant action of Alprax XR Tablet may be aggravated by concomitant use of other psychotropic drugs, anticonvulsants, antihistaminics, alcohol and oral contraceptives.
Alprax XR Tablet tablets should be stored in a cool and dry place, protected from light and moisture.
Alprax XR Tablet price in Bangladesh 11.20